
Britain's Medicines and Healthcare products Regulatory Agency (MHRA) has approved AstraZeneca Plc's (NASDAQ:AZN) antibody-based COVID-19 treatment to prevent infections in adults with poor immune response.
The approval covers Evusheld for adults who are not currently infected (or know exposure to) and for whom vaccination is not recommended.